Most regulatory headwinds remain for cannabis companies like Tilray.

Marijuana rescheduling may have taken place in the U.S., but that doesn't mean legalization will happen anytime soon.

The Trump administration recently rescheduled medical marijuana from a Schedule I to Schedule III substance.

Tilray CEO Irwin Simon sees a future where cannabis is treated like other medicine: prescribed by doctors and tailored to ...

Tilray (TLRY) stock jumped 14.2% Wednesday as Axios reported Trump's White House may reclassify cannabis to Schedule III, ...

Shares of Tilray Brands (NASDAQ:TLRY) are up roughly 10% in early Thursday trading, changing hands near $8.68 after the stock closed up 14% at $7.87 on Wednesday. The catalyst is growing speculation ...

The roller-coaster ride in the cannabis industry continued on Thursday as pot stocks that soared Wednesday on news of the U.S ...

Tilray surged on marijuana rescheduling excitement, but the stock faded once investors focused on how limited the immediate federal change could be.

The cannabis stock has lost around 96% of its value over the past five years.

Publicly traded cannabis stocks popped but have since eased back. The excitement and then caution has been a characteristic ...

The cannabis industry has spent years navigating regulatory uncertainty, limiting the growth and profitability of marijuana ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...